IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy
Angelo Sangiovanni(Ospedale Maggiore), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Edoardo G. Giannini(Ospedale Policlinico San Martino), Riccardo Gattai(University of Pisa), Guglielmo Borgia(University of Naples Federico II), Francesco Paolo Russo(University of Padua), Matteo Brunacci(University of Genoa), Gaia Pellegatta(Humanitas University), S. Maimone(University of Messina), Elia Biganzoli(Zimmer Biomet (Netherlands)), Luca Valenti(University of Milan), Roberto Filomia(University of Messina), Ilaria Serio(University of Bologna), M. Barone(University of Bari Aldo Moro), Erica Villa(University of Modena and Reggio Emilia), Giovanni Raimondo(University of Messina), N. Terreni(Ospedale Valduce), Maurizia Rossana Brunetto(University of Pisa), Luca Marzi(Azienda Ospedaliero-Universitaria di Modena), Filippo Oliveri(University of Pisa), Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Martina Gambato(University of Padua), Maria Grazia Rumi(University of Milan), L Belli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Eleonora Alimenti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 7
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821